MA45404A - Anticorps monoclonaux humanisés et chimériques dirigés contre cd81 - Google Patents

Anticorps monoclonaux humanisés et chimériques dirigés contre cd81

Info

Publication number
MA45404A
MA45404A MA045404A MA45404A MA45404A MA 45404 A MA45404 A MA 45404A MA 045404 A MA045404 A MA 045404A MA 45404 A MA45404 A MA 45404A MA 45404 A MA45404 A MA 45404A
Authority
MA
Morocco
Prior art keywords
chemerical
humanized
monoclonal antibodies
directed against
antibodies directed
Prior art date
Application number
MA045404A
Other languages
English (en)
French (fr)
Inventor
Chiung-Chi Kuo
Ronald Levy
Shoshana Levy
Jie Liu
Aurelien Marabelle
Ranjani Rajapaksa
Felipe Vences-Catalán
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MA45404A publication Critical patent/MA45404A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA045404A 2016-06-16 2017-06-14 Anticorps monoclonaux humanisés et chimériques dirigés contre cd81 MA45404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45404A true MA45404A (fr) 2019-04-24

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045404A MA45404A (fr) 2016-06-16 2017-06-14 Anticorps monoclonaux humanisés et chimériques dirigés contre cd81

Country Status (9)

Country Link
US (1) US10815306B2 (enExample)
EP (1) EP3471762A4 (enExample)
JP (1) JP2019517813A (enExample)
CN (1) CN109414492A (enExample)
BR (1) BR112018076247A2 (enExample)
CA (1) CA3027942A1 (enExample)
MA (1) MA45404A (enExample)
RU (1) RU2019100102A (enExample)
WO (1) WO2017218691A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US20140030771A1 (en) 2010-06-09 2014-01-30 Richard C. Yu Compositions and methods for increasing oil production and secretion
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
EP2650367A4 (en) * 2010-12-06 2015-07-08 Sumitomo Dainippon Pharma Co Ltd HUMAN MONOCLONAL ANTIBODY
US9725517B2 (en) * 2012-10-26 2017-08-08 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Humanized monoclonal antibodies against the extracellular domain of human death receptor 5

Also Published As

Publication number Publication date
EP3471762A1 (en) 2019-04-24
EP3471762A4 (en) 2020-03-11
CN109414492A (zh) 2019-03-01
BR112018076247A2 (pt) 2019-03-26
WO2017218691A1 (en) 2017-12-21
US10815306B2 (en) 2020-10-27
US20190177425A1 (en) 2019-06-13
RU2019100102A (ru) 2020-07-16
CA3027942A1 (en) 2017-12-21
JP2019517813A (ja) 2019-06-27
RU2019100102A3 (enExample) 2020-10-14

Similar Documents

Publication Publication Date Title
EP3325513B1 (en) Anti-PD-L1 antibodies and their uses
ZA201902533B (en) Anti-pd-l1 antibodies and variants
EP3817773A4 (en) Humanized antibodies against c-kit
EP3532489A4 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
DK3455257T3 (da) Anti-pd-l1-antistoffer
EP3426686C0 (en) Humanized Anti-PACAP Antibodies and Their Uses
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
IL250440B (en) Anti-her2 antibodies and immunoconjugates
IL286208A (en) Humanized influenza monoclonal antibodies and methods of use thereof
DK3389699T5 (da) Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf
EP3589648A4 (en) MONOCLONAL ANTI-RSV ANTIBODY FORMULATION
HRP20260436T1 (hr) Bispecifično protutijelo koje veže dll3 i cd3
SG11201705252UA (en) Anti-pd-1 monoclonal antibodies and obtaining method thereof
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
EP3363816A4 (en) ANTI-OX40 ANTIBODIES AND USES THEREOF
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
EP3480216A4 (en) ANTI-PCSK9 MONOCLONAL ANTIBODIES
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3487518A4 (en) HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
DK3356408T3 (da) Humaniserede anti-humane CD19-antistoffer og fremgangsmåder til anvendelse
IL248402B (en) Humanized antibodies against ceacam1
ZA202003858B (en) Monoclonal antibodies and methods for using same